121 related articles for article (PubMed ID: 10707728)
1. The impact of cisplat based chemotherapy on advanced ovarian cancer.
Prasad GR; Dalal AV; Tongaonkar HB; Chatterjee S; Kamat MR
J Postgrad Med; 1995; 41(4):95-8. PubMed ID: 10707728
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
7. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
8. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
9. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
10. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Israël L; Lepage E; Breau JL; Aguilera J
Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
[TBL] [Abstract][Full Text] [Related]
11. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin-based chemotherapy regimens.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1869-71. PubMed ID: 2697190
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
[TBL] [Abstract][Full Text] [Related]
14. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
Chylak V; Kolarić K; Krusić J
Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515
[No Abstract] [Full Text] [Related]
15. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer.
Hershman D; Jacobson JS; McBride R; Mitra N; Sundararajan V; Grann VR; Neugut AI
Gynecol Oncol; 2004 Aug; 94(2):540-9. PubMed ID: 15297201
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
[TBL] [Abstract][Full Text] [Related]
17. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
Raspagliesi F; Kusamura S; Campos Torres JC; de Souza GA; Ditto A; Zanaboni F; Younan R; Baratti D; Mariani L; Laterza B; Deraco M
Eur J Surg Oncol; 2006 Aug; 32(6):671-5. PubMed ID: 16621425
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
Bankhead C
J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116
[No Abstract] [Full Text] [Related]
19. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
20. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
